Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Update

Aprea Therapeutics, Inc. (NASDAQ:APRE) saw a large growth in short interest during the month of October. As of October 15th, there was short interest totalling 15,200 shares, a growth of 15.2% from the September 30th total of 13,200 shares. Currently, 0.3% of the company’s stock are sold short. Based on an average daily volume of 21,400 shares, the days-to-cover ratio is presently 0.7 days.

Aprea Therapeutics Trading Up 4.9 %

NASDAQ APRE opened at $4.28 on Tuesday. The company has a 50-day moving average price of $3.28 and a two-hundred day moving average price of $4.06. Aprea Therapeutics has a 52 week low of $2.15 and a 52 week high of $8.85. The stock has a market cap of $23.24 million, a price-to-earnings ratio of -1.29 and a beta of 1.03.

Aprea Therapeutics (NASDAQ:APRE) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.58) EPS for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.05. Aprea Therapeutics had a negative net margin of 1,012.37% and a negative return on equity of 56.38%. The business had revenue of $0.56 million for the quarter, compared to analyst estimates of $0.10 million. As a group, equities research analysts expect that Aprea Therapeutics will post -2.74 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Aprea Therapeutics in a research report on Thursday, October 24th. Wedbush reiterated an “outperform” rating and issued a $11.00 target price on shares of Aprea Therapeutics in a research note on Tuesday, August 13th.

Insider Buying and Selling at Aprea Therapeutics

In related news, Director Bernd R. Seizinger purchased 10,000 shares of the firm’s stock in a transaction dated Friday, October 11th. The stock was acquired at an average price of $2.68 per share, with a total value of $26,800.00. Following the completion of the transaction, the director now owns 44,730 shares of the company’s stock, valued at $119,876.40. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Marc Duey sold 6,462 shares of the business’s stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $4.58, for a total transaction of $29,595.96. Following the completion of the sale, the director now owns 233,651 shares of the company’s stock, valued at $1,070,121.58. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bernd R. Seizinger bought 10,000 shares of the firm’s stock in a transaction on Friday, October 11th. The stock was bought at an average price of $2.68 per share, with a total value of $26,800.00. Following the completion of the purchase, the director now owns 44,730 shares of the company’s stock, valued at $119,876.40. This trade represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired a total of 42,290 shares of company stock valued at $165,096 in the last three months. Corporate insiders own 12.80% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aprea Therapeutics stock. Stonepine Capital Management LLC acquired a new stake in shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 137,174 shares of the company’s stock, valued at approximately $558,000. Aprea Therapeutics makes up about 0.5% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 21st largest position. Stonepine Capital Management LLC owned approximately 2.53% of Aprea Therapeutics as of its most recent filing with the Securities and Exchange Commission. 34.19% of the stock is owned by institutional investors and hedge funds.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.